ABSTRACT
Background: Aim: To compare the concentration of secretory immunoglobulin-A (sIgA) in young adults with average or excellent aerobic capacity before and after a cardiopulmonary graded exercise test. Methods: Participants were nine apparently healthy physically active males (Mean age = 21.3 ± 2.1 yr.), randomly allocated in two groups based on their VO2max: a) average aerobic capacity (AEC, n = 5) or b) excellent aerobic capacity (EAC, n = 4). Participants performed the Bruce protocol to determine their aerobic capacity. The sIgA was measured before the test, immediately after the test and 60-, 120-, 240-, and 1440-min after the test. Results: Mixed factorial 2 x 6 ANOVA indicated no significant interactions between groups and measurements (p = 0.956), and main effect groups on sIgA (AEC = 85.4 ± 19.3 μg/mL vs. EAC = 79.2 ± 21.5 μg/mL, p = 0.836). Tukey's post hoc analysis revealed significant differences measurement obtained immediately after the test and between the initial measurement (p = 0.020), 60-min (p = 0.030), 240-min (p = 0.016), and 1440-min (p = 0.028) following the test. Conclusion: There is no change in sIgA kinetics depending on the aerobic capacity of the participants following an aerobic capacity cardiopulmonary graded exercise test.
Introducción. Objetivo: Comparar la cinética en la concentración de inmunoglobulina A salival (IgAs) en adultos jóvenes con capacidad aeróbica promedio (n: 5) o excelente (n: 4) antes y después de una prueba de esfuerzo. Método: 9 adultos jóvenes (edad 21,3 ± 2,1), divididos de acuerdo su VO2máx, realizaron una prueba de esfuerzo mediante el protocolo de Bruce. La concentración de IgAs fue determinada mediante el Salimetrics IgA Kit®, evaluando inicial, inmediatamente finalizada la prueba, +60, +120, +240, +1.440 min. Resultados: La prueba ANOVA 2x6 mixta indicó que no existieron interacciones significativas entre grupos y mediciones (p = 0,956). Tampoco se encontró una diferencia significativa en la media de IgAs en los grupos (Promedio = 85,4 ± 19.3 μg/mL vs Excelente=79,2 ± 21.5 μg/mL, p = 0,836). Independientemente de las mediciones, el análisis post hoc de Tukey indicó que las diferencias se encontraron en la medición obtenida inmediatamente después de la prueba y entre la medición inicial (p: 0,020), la medición obtenida 60 min (p: 0,030), 240 min (p: 0,016) y 1.440 min (p = 0,028) posteriores a la prueba. Conclusión: Los datos encontrados sugieren que no hay un cambio en la concentración de IgAs a través del tiempo en función de la capacidad aeróbica de los participantes.
Subject(s)
Humans , Male , Adult , Young Adult , Physical Endurance/physiology , Saliva/chemistry , Immunoglobulin A, Secretory/analysis , Anaerobic Threshold/physiology , Immunoglobulin A, Secretory/metabolism , Kinetics , Random Allocation , Cross-Sectional Studies , Exercise TestABSTRACT
The use of intravenous immunoglobulin (IVIG) is relatively in frequent in patients admitted to intensive care units (ICUs). However, off-label IVIG prescriptions for different conditions are highly prevalent. The aim of this paper is to review the existing evidence for the use of IVIG in patients admitted to ICUs, emphasizing non-infectious diseases and complications: hypogammaglobulinemia of the critically ill, hemophagocytic lymphohistiocytosis (HLH), Guillain-Barré syndrome (GBS), Kawasaki disease (KD), chylothorax, acute myocarditis, toxic shock syndrome (TSS), Stevens-Johnson syndrome (SJS)/toxic epidermalnecrolysis (TEN), and sepsis. In conclusion, in critically ill patients, IVIG use is of benefit in KD, GBS, and TSS. It may benefit patients with fulminant acute myocarditis. The benefit is not proven in patients with HLH, chylothorax, and SJS/TEN.
O uso de imunoglobulina intravenosa (IVIG) é relativamente infrequente em pacientes internados em unidades de terapia intensiva (UTIs). Entretanto, prescrições off-label de IVIG para diferentes patologias são altamente prevalentes. O objetivo deste artigo é revisar as evidências existentes para o uso de IVIG em pacientes internados em UTIs, enfatizando as doenças e complicações não infecciosas: hipogamaglobulinemia do paciente crítico, linfo-histiocitose hemofagocítica (HLH), síndrome de Guillain-Barré (GBS), doença de Kawasaki (KD), quilotórax, miocardite aguda, síndrome do choque tóxico (TSS), síndrome de Stevens-Johnson (SJS)/necrólise epidérmica tóxica (TEN), e sepse. Em conclusão, em pacientes criticamente enfermos, o uso de IVIG é benéfico em KD, GBS e TSS. IVIG pode ser benéfica em pacientes com miocardite aguda fulminante. O benefício não foi comprovado em pacientes com HLH, quilotórax e SJS/TEN.
Subject(s)
Humans , Immunoglobulins , Inpatients , Critical CareABSTRACT
Objetivo: A prevalência das doenças alérgicas vem aumentando nas últimas décadas em todo o mundo. A prevenção primária em lactentes considerados de alto risco para atopias, com base na alimentação no primeiro ano de vida, pode constituir uma importante forma de atuação na tentativa se minimizar as manifestações da doença. Fontes dos dados: O estudo foi realizado com base em artigos relacionados à prevenção de doenças alérgicas em crianças, disponíveis nos bancos de dados PUBMED, MEDLINE, SCIELO e LILACS nos últimos 10 anos, ou anteriores a esta data, mas relevantes do ponto de vista nutricional/epidemiológico. Síntese dos dados: A determinação dos lactentes de alto risco para doenças alérgicas é um dado de alta relevância para a instituição de medidas nutricionais preventivas no primeiro ano de vida. Não há evidências de que a restrição dietética da mãe durante a gestação ou período de amamentação possa ter algum benefício na prevenção de atopia no feto/lactente. Aleitamento materno, diminuição da carga alergênica na substituição ou complementação do leite materno e a presença de determinados nutrientes na alimentação infantil são possíveis intervenções para se minimizar as alergias ao longo da infância. Conclusões: Aleitamento materno exclusivo por seis meses, a utilização de fórmulas hidrolisadas como complemento ou substituição do leite materno e a introdução de alimentos sólidos após o 4° mês de vida são apontadas como as possíveis estratégias na prevenção primária de doenças alérgicas, no que concerne à alimentação do primeiro ano de vida.
Aim: The prevalence of allergic diseases has been increasing in the past decades around the world. Primary prevention in high risk infants to develop allergies, based on some feeding aspects in the first year of life seems to be an important form of sction in order to minimize allergic symptoms. Data source: The study was conducted based on related articles about prevention of allergic diseases in infants, available on PUBMED, MEDLINE, SCIELO and LILACS data bases in the last 10 years, or previous, but relevant regarding to nutritional or epidemiological point of view. Data synthesis: The recognition of high risk infants for developing allergic diseases is the most relevant information for establishing preventive feeding measurements in the first year of life. There is no evidence that restriction diet during pregnancy or breastfeeding are effective for reducing atopy in the fetus/infant. Breastfeeding, decreasing intake of allergenic proteins and the presence of appropriate nutritional elements are possibly effective interventions for prevention of allergy during the infancy. Conclusion: Exclusive breastfeeding up to six months of life, hydrolyzed formula as complementation or substitution to breast milk and delayed solid food introduction after the fourth month are possibly some strategies for the primary prevention of allergic diseases, regarding to feeding in the first year of life.
Subject(s)
Humans , Infant , Child , Antioxidants , Breast Feeding , Food Hypersensitivity , Hypersensitivity/pathology , Immunoglobulin E , Nutritional Sciences , Probiotics , Food , Methods , Patients , Primary Prevention , Diagnostic Techniques and ProceduresABSTRACT
Objective:To explore the effect of rhGH on apoptosis and the expression of P53 of IgA plasmocytes of intestinal wall after intestinal ischemia-reperfusion injury and the correlation between apoptosis and the expression of P53.Methods:60 Wistar rats were divided into two groups randomly:experiment group(1.33U/kg rhGH was given q.d) and control group.Each group was divided into 3 subgroups(2,4,6days,respectively).Apoptosis and the expression of P53 in IgA plasmocytes of ileal mucosal were observed.[WTH7X]Results:[WT5”XY](1)Apoptosis of IgA plasmocytes in experiment group was lower than that in control group on 2~ nd ,4~ th ,6~ th day and had statistical significance(P
ABSTRACT
Objetivo. Precisar si existe asociación entre enfermedad cardiovascular (ECV) y anticuerpos contra Chlamydia en población mexicana. Material y métodos. Estudio transversal, realizado en la Unidad de Investigación en Inmunología e Infectología -Hospital de Infectología del Centro Médico Nacional La Raza (CMNR)- y en el Servicio de Cirugía Cardiovascular y Asistencia Circulatoria, del Hospital General del CMNR, Instituto Mexicano del Seguro Social (IMSS), de agosto de 1998 a abril de 2000. Se determinaron anticuerpos IgG e IgM contra C. psittaci, C. trachomatis y C. pneumoniae mediante microinmunofluorescencia, en suero de 70 pacientes con ECV hospitalizados en el CMNR, mayores de 30 años, de uno u otro sexo, y se compararon con 140 sanos, pareados por edad y sexo. Se utilizaron muestras aleatorias simples, con un tamaño poblacional de 110, una prevalencia de 50 por ciento y un nivel de confianza de 99 por ciento. Para establecer la diferencia entre las proporciones de los títulos se utilizó ji cuadrada y se calculó la razón de momios. Resultados. El 94.3 por ciento (66/70) de los pacientes presentó IgG en contra de C. pneumoniae vs 37 por ciento (52/140) de los individuos sanos (p<0.001). Conclusiones. Existe una fuerte asociación entre anticuerpos IgG hacia C. pneumoniae y ECV.
Objective. To evaluate the association between cardiovascular disease (CVD) and antibodies against Chlamydia in Mexican population. Material and Methods. A cross-sectional study was conducted from August 1988 to April 2000, at the Immunology and Infectology Research Unit of Hospital de Infectología, Centro Médico Nacional La Raza (CMNR)- and at the Cardiovascular Surgery and Circulatory Care, Hospital General CMNR, Instituto Mexicano del Seguro Social (IMSS). Study subjects were 70 CVD hospitalized patients, older than 30 years, from both genders. Serum IgG and IgM antibodies against C. psitaccii, C. trachomatis and C. pneumoniae were determined by microimmunofluorescence in study subjects and compared with those from 140 healthy individuals, matched by age and sex. Simple random sampling was used, for an expected prevalence of 50 percent and a 99 percent confidence level; the sample size was 110 subjects. The chi-squared test and odds ratios were used to compare proportions. Results. IgG antibodies against C. pneumoniae were found in 94.3 percent (66/70) patients, as compared to only 37 percent (52/140) of healthy individuals (p<0.001). Conclusions. An association between IgG antibodies against C. pneumoniae and CVD was found. This finding warrants further studies to evaluate the role of C. pneumoniae as a predictor of CVD.